COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,788 Articles (22,946 medRxiv, 8,842 bioRxiv)

Most recent first Previous |  Page 2358: Articles 23571-23580  | Next

MAIT cell activation and dynamics associated with COVID-19 disease severity and outcome
Parrot, T., Gorin, J.-B., Ponzetta, A., Maleki, K. T., Kammann, T., Emgard, J., Perez Potti, A., Sekine, T., Rivera-Ballesteros, O., Karolinska COVID-19 Study Group, , Folkesson, E., Rooyackers, O., Eriksson, L. I., Norrby-Teglund, A., Ljunggren, H.-G., Bjorkstrom, N. K., Aleman, S., Buggert, M., Klingstrom, J., Stralin, K., Sandberg, J. K.
10.1101/2020.08.27.20182550 — Posted: 2020-09-01
The Potential Role of Extracellular Vesicles in COVID-19 Associated Endothelial injury and Pro-inflammation
Krishnamachary, B., Cook, C., Spikes, L., Chalise, P., Dhillon, N. K.
10.1101/2020.08.27.20182808 — Posted: 2020-09-01 Discussion: Onsite
Changes in social behavior over time in the COVID-19 pandemic
Sheehan, M. M., Pfoh, E. R., Speaker, S., Rothberg, M. B.
10.1101/2020.08.27.20183376 — Posted: 2020-09-01
Towards a digital solution: Predicting public take-up of Singapore's contact tracing application during the COVID-19 crisis
Saw, Y. E., Tan, E. Y.-Q., Liu, J. S., Liu, J. C.
10.1101/2020.08.26.20182386 — Posted: 2020-09-01
Covid-19 Social Distancing Interventions by State Mandate and their Correlation to Mortality in the United States
McCafferty, S., Ashley, S.
10.1101/2020.08.26.20182758 — Posted: 2020-09-01
Do Lockdowns Bring about Additional Mortality Benefits or Costs? Evidence based on Death Records from 300 Million Chinese People
Qi, J., Zhang, D., Zhang, X., Yin, P., Liu, J., Pan, Y., Takana, T., Xie, P., Wang, Z., Liu, S., Gao, G. F., He, G., Zhou, M.
10.1101/2020.08.28.20183699 — Posted: 2020-09-01
On Statistical Power for Case-Control Host Genomic Studies of COVID-19
Lin, Y.-C., Brooks, J. D., Bull, S. B., Gagnon, F., Greenwood, C. M., Hung, R. J., Lawless, J., Paterson, A., Sun, L., Strug, L. J.
10.1101/2020.08.26.20182840 — Posted: 2020-09-01
Systematic review and meta-analysis identifies potential host therapeutic targets in COVID-19.
Parkinson, N., Rodgers, N., Head Fourman, M., Wang, B., Zechner, M., Swets, M., Millar, J. E., Law, A., Russell, C., Baillie, J. K., Clohisey, S.
10.1101/2020.08.27.20182238 — Posted: 2020-09-01
County-level exposures to greenness and associations with COVID-19 incidence and mortality in the United States
Klompmaker, J. O., Hart, J. E., Holland, I., Sabath, M. B., Wu, X., Laden, F., Dominici, F., James, P.
10.1101/2020.08.26.20181644 — Posted: 2020-09-01 Discussion: Onsite
Post-COVID-19 Functional Status: Relation to age, smoking, hospitalization and comorbidities
Mohamed-Hussein, A., Galal, I., Saad, M., Zayan, H. E., Abdelsayed, M., Moustafa, M., Ezzat, A. R., Helmy, R., Abd Elaal, H., Aly, K., Abderheem, S.
10.1101/2020.08.26.20182618 — Posted: 2020-09-01

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).